About this episode

Dr. Rahul Banerjee discusses the latest updates to the ASCO living guideline on the treatment of multiple myeloma, highlighting new recommendations based on recent trial results.

Dr. Rahul Banerjee joins the podcast to discuss the latest update to the living guideline on the treatment of multiple myeloma. He explains how sensational results from the MajesTEC-3 trial, which evaluated teclistamab plus daratumumab, prompted a major shift in the recommendations for patients with relapsed or refractory disease. Dr. Banerjee details why immunotherapies, specifically CAR T-cell therapy and bispecific antibodies, are now the preferred treatment options at first relapse over traditional triplets. He also provides context on evidence that did not lead to recommendation changes, the importance of individualized decision-making when choosing between immunotherapy options, and what future updates may be on the horizon, including data on CELMoDs. Read the full living guideline, "Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1," at www.ascopubs.org/guidelines/treatment-multiple-myeloma-asco-living-guideline

People in this episode

Guest: Dr. Rahul Banerjee

Topics covered

• multiple myeloma
• treatment guidelines
• immunotherapy
• CAR T-cell therapy
• bispecific antibodies
• personalized medicine

Keywords

• multiple myeloma
• ASCO guidelines
• immunotherapy
• CAR T-cell therapy
• daratumumab
• teclistamab
• MajesTEC-3 trial
• personalized treatment

Mentioned in this episode

Organizations: American Society of Clinical Oncology

Products: teclistamab, daratumumab, CAR T-cell therapy, bispecific antibodies

Books & works: Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1

More episodes of ASCO Guidelines

• Circulating Tumor DNA Testing in Solid Tumors and Lymphoma Guideline · June 18, 2026 · 18 min
• Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2 · May 26, 2026 · 19 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 1 · May 26, 2026 · 13 min

Explore listener stats, chart rankings, contacts and more on the ASCO Guidelines podcast page.